Dark

Check out our Level2View

ATXI
AVENUE THERAPEUTICS INC
stock OTC

EOD

Jul 30, 2026

0.3877USD+8.904%(+0.0317)6,543

Pre-market

0.00USD-100.000%(-0.30)0

After-hours

0.00USD0.000%(0.00)0

OverviewHistoricalExchangesShortsNews

Jan 7, 2022

04:27PM EST Avenue Therapeutics Announces Joseph Vazzano Notified The Co. That He Was Resigning From CFO; The Company's Board Of Directors Appointed Dr. Lucy Lu, M.D. As The Company's Interim Chief Financial Officer Benzinga

Dec 15, 2021

12:00PM EST Avenue Therapeutics Announces Closing of Public Offering of Common GlobeNewswire Inc

Dec 13, 2021

12:57PM EST Avenue Therapeutics Late Sunday Priced ~1.91M Share Offering At $1.07/Share Benzinga

Dec 12, 2021

08:00PM EST Avenue Therapeutics Prices $2.0 Million Underwritten Public GlobeNewswire Inc

Nov 29, 2021

08:27AM EST Avenue Announces FDA Panel Meeting To Review IV Tramadol NDA Tentatively Scheduled For Feb 15 RTTNews

08:03AM EST Avenue Therapeutics Announces FDA Advisory Committee Meeting To Review IV Tramadol NDA Tentatively Scheduled For February 15, 2022 Benzinga

08:00AM EST Avenue Therapeutics Announces FDA Advisory Committee Meeting to GlobeNewswire Inc

Nov 17, 2021

09:30AM EST Avenue Therapeutics Announces Exercise and Closing of GlobeNewswire Inc

Nov 12, 2021

09:20AM EST Avenue Therapeutics Announces Closing of Public Offering of Common GlobeNewswire Inc

Nov 10, 2021

08:23AM EST The Daily Biotech Pulse: Valneva Inks COVID-19 Vaccine Supply Contract In Europe, I-Mab Spikes On China Deal, DermTech Sinks On Guidance Benzinga

06:06AM EST The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 05.30 A.M. ET). RTTNews

Oct 25, 2021

07:10AM EDT Avenue Therapeutics Receives Interim Response To Its Formal Dispute Resolution Request From US Food And Drug Administration Office Of New Drugs Benzinga

07:00AM EDT Avenue Therapeutics Receives Interim Response to its Formal GlobeNewswire Inc

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Oct 6, 2021

07:33AM EDT The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal Benzinga

Oct 5, 2021

08:01AM EDT The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout Benzinga

Sep 30, 2021

07:43AM EDT The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug Benzinga

Sep 21, 2021

08:20AM EDT The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Jul 28, 2021

07:33AM EDT The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal Benzinga

Jul 27, 2021

11:13AM EDT The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts Benzinga

Jul 20, 2021

08:20AM EDT The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street Benzinga

Jul 16, 2021

07:37AM EDT The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study Benzinga

Jul 15, 2021

08:08AM EDT The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs Benzinga

Jul 14, 2021

07:48AM EDT The Daily Biotech Pulse: ScPharma's Positive Data, Lilly Goes Shopping, LeMaitre Pre-Announces Q2 Revenues Benzinga

Jun 16, 2021

05:02AM EDT 44 Biggest Movers From Yesterday Benzinga

Jun 15, 2021

08:07AM EDT The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda Benzinga

Jun 14, 2021

02:47PM EDT Mid-Afternoon Market Update: Dow Tumbles 250 Points; Enochian Biosciences Shares Spike Higher Benzinga

12:25PM EDT Mid-Day Market Update: Nasdaq Rises Over 50 Points; Washington Prime Group Shares Plunge Benzinga

10:29AM EDT Mid-Morning Market Update: Markets Mostly Lower; Accenture To Acquire German Engineering Company Benzinga

08:22AM EDT Benzinga Pro's Top 5 Stocks To Watch For Monday, June 14, 2021: CRSR, RIDE, ITOS, ATXI, ENOB Benzinga

07:38AM EDT Specialty pharmaceutical company Avenue Therapeutics, Inc. (ATXI) announced Monday that it has received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) seeking approval for intravenous or IV tramadol. RTTNews

07:35AM EDT Avenue Therapeutics Shares Resume Trading Benzinga

07:27AM EDT Avenue Therapeutics Receives Second CRL From FDA Regarding NDA Seeking Approval For IV Tramadol RTTNews

07:15AM EDT CORRECTION: Avenue Therapeutics Ticker Is 'ATXI' Benzinga

07:14AM EDT Avenue Therapeutics Receives Complete Response Letter From FDA For IV Tramadol; CRL States That 'the delayed and unpredictable onset of analgesia with IV tramadol does not support its benefit as a monotherapy to treat patients in acute pain' Benzinga

07:00AM EDT Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that it has received a second Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding its New Drug Application (NDA) seeking approval for IV tramadol. GlobeNewswire Inc

06:59AM EDT Avenue Therapeutics Shares Halted, News Pending Benzinga

Jun 3, 2021

08:02AM EDT Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics Benzinga

Apr 23, 2021

11:37PM EDT Pomerantz LLP is investigating claims on behalf of investors of Avenue Therapeutics Inc. (Avenue or the Company) (NASDAQ:ATXI). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. GlobeNewswire Inc

Apr 13, 2021

02:30PM EDT Mid-Afternoon Market Update: Dow Falls 75 Points; vTv Therapeutics Shares Spike Higher Benzinga

12:28PM EDT Mid-Day Market Update: Nasdaq Jumps 100 Points; Avenue Therapeutics Shares Slide Benzinga

10:16AM EDT Mid-Morning Market Update: Markets Mixed; Fastenal Profit Tops Estimates Benzinga

06:51AM EDT Avenue Therapeutics, Inc. (ATXI) said the FDA was still reviewing its New Drug Application for IV tramadol. The NDA was resubmitted following the receipt of official minutes from a Type A meeting with the FDA, which was conducted following a CRL issued by the FDA in October 2020. The resubmission had been assigned a PDUFA goal date of April 12, 2021. RTTNews

06:35AM EDT Avenue Therapeutics Says FDA Is Still Reviewing NDA Resubmission For IV Tramadol RTTNews

06:32AM EDT Avenue Therapeutics Announces FDA Is Still Reviewing Its NDA Resubmission For IV Tramadol And has Not Provided Decision Benzinga

06:30AM EDT Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that the U.S. Food and Drug Administration (FDA) was still reviewing its New Drug Application (NDA) for IV tramadol and had not provided a decision regarding the NDA. GlobeNewswire Inc

Apr 10, 2021

09:19AM EDT The Week Ahead In Biotech (April 11-17): Avenue Therapeutics FDA Decision and Conference Presentations In The Spotlight Benzinga

Dec 18, 2020

08:00AM EST Avenue Therapeutics Announces Publication of Tramadol Non-Medical GlobeNewswire Inc

08:00AM EST Avenue Therapeutics Announces Publication of Real-World Data on GlobeNewswire Inc

Dec 17, 2020

10:23AM EST Shares of specialty pharmaceutical company, Avenue Therapeutics, Inc. (ATXI) are surging more than 16% Thursday morning after the company provided a regulatory update following receipt of the official meeting minutes from a November 2020 Type A meeting with the FDA relating to a path forward for its intravenous tramadol. RTTNews

07:00AM EST Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today provided a regulatory update following receipt of the official meeting minutes from a November 2020 Type A meeting with the U.S. Food and Drug Administration (FDA) relating to a path forward for IV tramadol. GlobeNewswire Inc

Oct 29, 2020

07:30AM EDT The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal Benzinga

Oct 27, 2020

08:25AM EDT The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings Benzinga

Oct 22, 2020

10:26AM EDT Stocks Trading Near 52-Week Lows Just After Open On Thursday, Oct. 22, 2020: PBT, HYLN, SNP, ATXI, VLDR, BP, AACQ, JAGX, GP, YGMZ, RMRM, RMTI, TMX Benzinga

07:52AM EDT The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat Benzinga

Oct 21, 2020

08:04AM EDT The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings Benzinga

Oct 14, 2020

08:58PM EDT SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of PR Newswire

Oct 12, 2020

02:35PM EDT Mid-Afternoon Market Update: Dow Jumps 350 Points; Acorn International Shares Climb Benzinga

01:35PM EDT Avenue Therapeutics Sinks As FDA Rejects Opioid Pain Drug On Safety Concerns Benzinga

01:29PM EDT Mid-Day Market Update: Crude Oil Down 3%; Dillard's Shares Spike Higher Benzinga

10:23AM EDT Shares of Avenue Therapeutics, Inc. (ATXI) more-than-halved on Monday morning after the FDA said it can't approve Tramadol's NDA in its present form. RTTNews

10:23AM EDT Mid-Morning Market Update: Markets Open Higher; Huya and DouYu To Merge Benzinga

06:58AM EDT Avenue Therapeutics Receives Complete Response Letter From FDA Regarding NDA For IV Tramadol RTTNews

06:33AM EDT Avenue Therapeutics Receives Complete Response Letter from the FDA for IV Tramadol Benzinga

06:30AM EDT Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Companys New Drug Application (NDA) for IV tramadol. GlobeNewswire Inc

Sep 9, 2020

08:12AM EDT Avenue Therapeutics Announces Publication Of Report Titled 'IV tramadol: A novel option for US patients with acute painA review of its pharmacokinetics, abuse potential and clinical safety record' Benzinga

08:00AM EDT Avenue Therapeutics Announces Publication of a Review of IV Tramadol GlobeNewswire Inc

Aug 14, 2020

07:34AM EDT Avenue Therapeutics Q2 EPS $(0.11) Up From $(0.43) YoY Benzinga

07:30AM EDT Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today reported financial results and recent corporate highlights for the second quarter ended June 30, 2020. GlobeNewswire Inc

Aug 12, 2020

07:30AM EDT Fortress Biotech Announces Virtual Two-Day Corporate Access Summit GlobeNewswire Inc

Jul 21, 2020

08:35AM EDT Avenue Therapeutics Announces Publication Of Phase 3 Bunionectomy Study Results Benzinga

08:30AM EDT Avenue Therapeutics, Inc. (NASDAQ: ATXI) (Avenue), a company focused on the development of intravenous (IV) tramadol for the U.S. market, today announced that the results from its Phase 3 study of IV tramadol in patients undergoing bunionectomy have been published in the peer-reviewed journal, Pain and Therapy. GlobeNewswire Inc

Share